ClinVar Miner

Submissions for variant NM_007294.3(BRCA1):c.670+16G>A (rs199916228)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV001003384 SCV001161593 benign Breast-ovarian cancer, familial 1 2019-06-18 reviewed by expert panel curation IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 1 based on posterior probability = 1.35E-06
Ambry Genetics RCV000131335 SCV000186309 likely benign Hereditary cancer-predisposing syndrome 2015-08-05 criteria provided, single submitter clinical testing This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
GeneDx RCV000444606 SCV000512281 benign not specified 2015-05-07 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Invitae RCV001079367 SCV000560302 benign Hereditary breast and ovarian cancer syndrome 2020-12-01 criteria provided, single submitter clinical testing
Color Health, Inc RCV000131335 SCV000683342 likely benign Hereditary cancer-predisposing syndrome 2017-01-17 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000587845 SCV000699285 likely benign not provided 2017-02-13 criteria provided, single submitter clinical testing Variant summary: The BRCA1 c.670+16G>A variant involves the alteration of a non-conserved intronic nucleotide. One in silico tool predicts a benign outcome for this variant. This variant was found in 5/103692 control chromosomes at a frequency of 0.0000482, which does not exceed the estimated maximal expected allele frequency of a pathogenic BRCA1 variant (0.0010005). However, this variant, which is found in 11 patients in the UMD database and 2 families in kConFab, is reported as co-occurring with a pathogenic variant in BRCA2 (c.7795_7797delGAA (p.Glu2599del)). Multiple clinical diagnostic laboratories/reputable databases classified this variant as "likely benign/polymorphysm". Similarly, 4/5 in silico tools (via Alamut) predict that this variant does not affect the normal splicing pattern and in functional studies the variant was shown to increase exon 10 inclusion (Steffensen_EJHG_2014). Taken together, this data strongly support non-pathogenicity, therefore the variant was classified as likely benign.
Department of Pathology and Laboratory Medicine,Sinai Health System RCV001353415 SCV000591292 likely benign Malignant tumor of breast no assertion criteria provided clinical testing The BRCA1 c.670+16G>A variant was identified in 1 of 2662 proband chromosomes (frequency: 0.0004) from individuals or families with breast and ovarian cancer (Hansen 2011). The variant was also identified in dbSNP (ID: rs199916228) as “With likely benign allele”, Clinvitae database (as likely benign by ClinVar), the ClinVar database (as likely benign by Ambry Genetics) and Fanconi Anemia Mutation Database (LOVD) (probably affects function). This variant was identified in the 1000 Genomes Project in 1 of 5000 chromosomes (frequency: 0.0002), NHLBI GO Exome Sequencing Project in 1 of 8600 European American alleles (freq. 0.0001) and Exome Aggregation Consortium database (March 14, 2016) in 5 of 103692 chromosomes (freq. 0.00005) in the following populations: European (Non-Finnish) in 4 of 56110 chromosomes (freq. 0.00007), South Asian in 1 of 14482 chromosomes (freq. 0.00007), although this low number of observations and low frequency is not substantive enough to determine the prevalence of the variant in the general population and its relationship to disease. The c.670+16G>A variant is located in the 5' splice region but does not affect the invariant +1 and +2 positions. However, positions +3 to +6 are part of the splicing consensus sequence and variants involving these positions sometimes affect splicing. In addition, 1 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing. The population study by Hansen (2011) identify the variant together with a disease-causing mutation, deletion of exon 18 and 19 in BRCA1, suggesting that this variant could be benign polymorphisms. However, the functional study by Steffensen (2014) observed the variant induced almost complete inclusion of exon 10 – an exon known to be involved in alternative splicing and therefore classified the variant as uncertain significance. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign.
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen RCV000587845 SCV001744364 likely benign not provided no assertion criteria provided clinical testing
Human Genetics - Radboudumc,Radboudumc RCV000587845 SCV001959656 likely benign not provided no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.